Syneos Health, Inc.

NasdaqGS:SYNH Stock Report

Market Cap: US$4.5b

Syneos Health Valuation

Is SYNH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYNH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYNH ($42.98) is trading below our estimate of fair value ($57.57)

Significantly Below Fair Value: SYNH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNH?

Key metric: As SYNH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SYNH. This is calculated by dividing SYNH's market cap by their current earnings.
What is SYNH's PE Ratio?
PE Ratio62.6x
EarningsUS$71.22m
Market CapUS$4.46b

Price to Earnings Ratio vs Peers

How does SYNH's PE Ratio compare to its peers?

The above table shows the PE ratio for SYNH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.9x
SHC Sotera Health
53.2x41.0%US$3.8b
STVN Stevanato Group
46.9x20.0%US$5.6b
BRKR Bruker
28.3x15.8%US$8.6b
CRL Charles River Laboratories International
23x12.1%US$9.5b
SYNH Syneos Health
62.6x33.7%US$4.5b

Price-To-Earnings vs Peers: SYNH is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the peer average (29x).

Price to Earnings Ratio vs Industry

How does SYNH's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.3xn/aUS$325.01k
No more companies available in this PE range
SYNH 62.6xIndustry Avg. 36.2xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SYNH is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the US Life Sciences industry average (35.4x).

Price to Earnings Ratio vs Fair Ratio

What is SYNH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio62.6x
Fair PE Ratio29.8x

Price-To-Earnings vs Fair Ratio: SYNH is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the estimated Fair Price-To-Earnings Ratio (29.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYNH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Dec ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Nov ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Oct ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Sep ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Aug ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Jul ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Jun ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
May ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Apr ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Mar ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Feb ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Jan ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Dec ’24n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Nov ’24n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Oct ’24US$42.98
US$42.63
-0.8%
2.3%US$43.00US$40.00n/a8
Sep ’24US$42.72
US$42.67
-0.1%
2.2%US$43.00US$40.00n/a9
Aug ’24US$42.36
US$42.70
+0.8%
2.1%US$43.00US$40.00n/a10
Jul ’24US$42.14
US$42.70
+1.3%
2.1%US$43.00US$40.00n/a10
Jun ’24US$41.55
US$42.70
+2.8%
2.1%US$43.00US$40.00n/a10
May ’24US$39.38
US$41.30
+4.9%
18.1%US$55.00US$28.00n/a10
Apr ’24US$35.62
US$42.00
+17.9%
17.8%US$55.00US$28.00n/a10
Mar ’24US$40.06
US$42.30
+5.6%
18.3%US$55.00US$28.00n/a10
Feb ’24US$37.76
US$41.23
+9.2%
37.7%US$82.00US$25.00n/a11
Jan ’24US$36.68
US$41.05
+11.9%
37.9%US$82.00US$27.00n/a11
Dec ’23US$35.96
US$43.59
+21.2%
39.2%US$82.00US$27.00n/a11

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/29 02:51
End of Day Share Price 2023/09/27 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Syneos Health, Inc. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory BolanAvondale Partners
Eric ColdwellBaird
Stewart GlickmanCFRA Equity Research